Novel Three-Drug Regimen for Extensively Drug-Resistant Tuberculosis

A 26-week oral regimen of bedaquiline, pretomanid, and linezolid was 90% effective in treating patients with XDR-TB.

Current management of extensively drug-resistant tuberculosis (XDR-TB) infections having resistance to agents including isoniazid, rifampin, fluoroquinolones, and aminoglycosides has no standard recommended regimen. Patients generally receive up to 24 months of multiple agents with substantial adverse effects and cure rates of about 14%. Two new agents, bedaquiline and pretomanid, have shown activity against XDR-TB; thus, investigators performed an open-label study in South Africa of a 26-week course of these agents plus linezolid in patients with XDR-TB or complicated multidrug resistant tuberculosis (MDR-TB). Participants received oral bedaquiline (400 mg daily for 2 weeks, then 200 mg thrice weekly for 24 weeks), pretomanid (200 mg daily…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Novel Three-Drug Regimen for Extensively Drug-Resistant Tuberculosis

Topics

Reviewing Author